Change of Director's Interest Notice - Pasquale Rombola
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
Microba Life Sciences Limited
ABN
82 617 096 652
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Mr Pasquale Rombola
Date of last notice
8 November 2022
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
1. Rombola Family Pty Ltd <Rombola Family A/C>. Pasquale
Rombola is the sole director and sole shareholder of Rombola
Family Pty Ltd and a beneficiary of the Rombola Family Trust
Note: Provide details of the circumstances
giving rise to the relevant interest.
2. Rombola Superannuation Pty Ltd <Rombola Super Fund A/C>.
Pasquale Rombola is a director and a shareholder of Rombola
Superannuation Pty Ltd and a beneficiary of the Rombola Super
Fund.
Date of change
25, 27 & 30 October 2023
No. of securities held prior
to change
1. 5,200,000 Ordinary Shares
300,000 Options exercisable at $0.675, expiring 29 April 2025.
Class
Ordinary Shares
Number acquired
1. 400,000
2. 170,000
Number disposed
-
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
includes brokerage/gst
$128,830.22
No. of securities held after
change
1. 5,600,000 Ordinary Shares
300,000 Options exercisable at $0.675, expiring 29 April 2025.
2. 170,000 Ordinary Shares
Nature of change
On-market purchase of 170,000 shares for a total consideration of
$36,830.22 and the part take-up of 400,000 entitlement shares under
the institutional component of the Entitlement Offer for a total
consideration of $92,000.00.
Note: If consideration is non-cash, provide
details and estimated valuation
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the interest
has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade
to proceed during this period?
No
If prior written clearance was provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
N/A
Share your feedback
Discover